By ipomarket.in Editorial Team · Last reviewed: 2026-11-05
Disclaimer: This article is for informational purposes only and does not constitute investment advice. IPO investments are subject to market risks. Please read the offer document carefully and consult a SEBI-registered investment advisor before investing.
Ask most retail investors what they check before an IPO lists, and the answer is often the same: the GMP. The Grey Market Premium has become the shorthand for whether an issue is "hot" or not. But the number carries far more weight in conversation than its track record justifies. This article walks through what GMP is, how accurate it has actually been, and where it quietly fails.
What the grey market and GMP actually are
The grey market is an unofficial market where IPO securities are traded before they officially list on the exchanges. Grey Market Premium (GMP) is the premium at which these IPO shares are informally priced above, or below, the IPO issue price.
The word "unofficial" is doing a lot of work here. The grey market operates entirely outside SEBI's regulatory framework. GMP transactions fall outside the jurisdiction of the Securities Contracts (Regulation) Act and the SEBI Act, which means there is no legal protection and no civil enforcement mechanism if a deal goes wrong. These transactions lack formal agreements, are cash-based, and are driven entirely by mutual trust with no counterparty legal recourse.
Most of this activity is reportedly concentrated in select cities in Gujarat and Mumbai and carried out by a small group of individuals. So when you read a GMP figure online, you are looking at a sentiment reading from a narrow, opaque corner of the market, not a regulated price.
If you want a fuller primer on the mechanics, our explainer on what IPO GMP is and how it works covers the basics.
So how accurate is GMP?
This is where the picture gets interesting, because the honest answer is: it depends heavily on the size of the premium and the type of IPO.
Direction vs magnitude
According to ipomarket.in's own accuracy tracking, GMP correctly predicted the listing direction (whether a stock would open above or below its issue price) 80% of the time across 185 tracked IPOs in 2026. Practitioners cited by SMC Trade Online report a similar directional accuracy of roughly 70-85%, while noting that the magnitude of GMP often diverges sharply from actual listing prices.
That gap between direction and magnitude is the crux of the whole debate. Knowing a stock is likely to list up is not the same as knowing by how much.
The magnitude story
An analysis cited by DataDaemon, which reviewed Indian IPOs listed in 2026, reportedly found that the median IPO listed exactly at its GMP, and 69% of listings landed within 10 percentage points of the GMP prediction. For IPOs with a moderate GMP, in the 10-50% premium range, the median listing gain reportedly matched the median GMP almost exactly.
That sounds encouraging until you look at the extremes.
Thin premiums are close to a coin toss
The same 2026 analysis reportedly found that when GMP was a small positive number, under 5%, 20 of 64 such IPOs still ended up listing below the issue price. In other words, a thin premium is closer to a coin toss than a reliable signal. If an IPO shows a wafer-thin GMP, treating it as a near-certain pop would be a mistake.
Mainboard vs SME
The type of IPO matters too. Per ipomarket.in's tracking, mainboard GMP has been more reliable than SME GMP, with 91% accuracy versus 85% accuracy in 2026. SME grey markets are thinner and easier to distort, so their premiums deserve extra scepticism. Our note on GMP accuracy and data reliability goes deeper on these distinctions.
What the academic view says
The research literature is more cautious than the practitioner data. One academic study referenced by SMC Trade Online reportedly found no statistically significant link between GMP and the actual listing price. A separate paper (SSRN) reportedly concluded that grey market premiums are generally unbiased predictors of actual listing prices, but with an important caveat: IPOs with high GMP tend to experience greater underpricing.
These two findings are not as contradictory as they first appear. GMP can be directionally useful on average while still being an unreliable point forecast for any single IPO, especially at the high end where enthusiasm runs ahead of fundamentals.
The limits worth remembering
The consensus across sources is consistent. GMP reflects sentiment and shows momentum shifts, but it is not a reliable forecast of the listing price and is no substitute for fundamental analysis. It should be viewed as an informal market indicator rather than a confirmed outcome. It can give useful clues about demand, but it is informal, volatile and easily distorted.
Perhaps the sharpest point: GMP may show which IPO is attracting attention, but it says little about business quality, valuation discipline or long-term returns. A high premium tells you a stock is in demand right now, not that the company is worth owning in three years.
For investors who want to move beyond the premium, our guide on what GMP tells you versus business quality is a useful counterweight.
Is a regulated alternative coming?
There are signs the regulator wants to bring this activity into the open. In January 2025, the SEBI chairperson reportedly announced that SEBI plans to develop a "when-listed" platform to allow regulated trading of IPO shares after allotment but before listing, specifically aimed at curbing grey market activity. If it materialises, such a platform could give investors a transparent, enforceable price signal to replace the informal GMP.
It is worth remembering how short the pre-listing window already is. The IPO-to-listing timeline in India is T+3, meaning three working days from issue closure, mandatory since December 2023 under a SEBI circular. The grey market, in effect, exists to price a gap that is only three days long.
How to use GMP sensibly
None of this makes GMP useless. Used carefully, it is one input among several:
- Treat it as a sentiment gauge, not a price target.
- Weight mainboard GMP more than SME GMP.
- Be especially sceptical of thin premiums under 5%, which have behaved closer to a coin toss.
- Never let GMP replace reading the offer document and checking the financials.
The number is informal, it is unregulated, and its accuracy swings with the size of the premium and the type of issue. Respect those boundaries and GMP becomes a modest signal rather than a false promise.
FAQ
Is GMP a reliable predictor of IPO listing price?
It is a reasonable directional indicator and a weak magnitude indicator. ipomarket.in tracking found GMP predicted listing direction 80% of the time across 185 IPOs in 2026, and the median 2026 IPO reportedly listed exactly at its GMP. But academic research referenced by SMC Trade Online reportedly found no statistically significant link to the actual listing price, so it should never be treated as a confirmed outcome.
Is the grey market legal in India?
The grey market operates entirely outside SEBI's regulatory framework. GMP transactions fall outside the Securities Contracts (Regulation) Act and the SEBI Act, so there is no legal protection and no civil enforcement mechanism for disputes. Deals are cash-based and run on mutual trust with no counterparty recourse.
Why is SME GMP less reliable than mainboard GMP?
Per ipomarket.in's 2026 tracking, mainboard GMP showed 91% accuracy versus 85% for SME GMP. SME grey markets are thinner and easier to distort, which makes their premiums more prone to manipulation and sharp swings.
Should I trust a very small GMP?
Be cautious. The 2026 analysis cited by DataDaemon reportedly found that among IPOs with a GMP under 5%, 20 of 64 still listed below the issue price. A thin premium behaves closer to a coin toss than a dependable signal.
Is SEBI planning to replace the grey market?
In January 2025, the SEBI chairperson reportedly announced plans for a "when-listed" platform to allow regulated trading of IPO shares after allotment but before listing, aimed at curbing grey market activity. As of now it remains a stated plan, not a live product.
Last reviewed: 2026-11-05 by the ipomarket.in Editorial Team.